Journal of addiction psychiatry最新文献

{"title":"Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.","authors":"Kenneth Blum, David Baron, Thomas McLaughlin, Panayotis K Thanos, Catherine Dennen, Mauro Ceccanti, Eric R Braverman, Alireza Sharafshah, Kai-Uwe Lewandrowski, John Giordano, Rajendra D Badgaiyan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Annotated bibliography of genetic addiction risk severity (GARS) publications, pro-dopamine regulation in nutraceuticals (KB220 nutraceutical variants), and policy documents. Further research is required to encourage the field to consider \"Reward Deficiency Syndrome (RDS) Anti-addiction Modeling\" which involves early risk identification by means of genetic assessment similar to GARS, followed by induction of dopamine homeostasis by means of genetically guided pro-dopamine regulation similar to KB220. These results suggest that genetically based treatments may be a missing piece in the treatment of substance use disorder (SUD).</p>","PeriodicalId":73582,"journal":{"name":"Journal of addiction psychiatry","volume":"8 1","pages":"1-33"},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders.","authors":"Gianni Martire, Daniel Sipple, David Baron, Mark S Gold, Kai-Uwe Lewandowski, Catherine A Dennen, Alireza Sharafshah, Igor Elman, Panayotis K Thanos, Edward J Modestino, Rajendra D Badgaiyan, Albert Pinhasov, Abdalla Bowirrat, Milan Makale, A Kenison Roy, Keerthy Sunder, Kevin T Murphy, Shaurya Mahajan, Yatharth Mahajan, Chynna Levin, Kenenth Blum","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) share overlapping neurobiological mechanisms particularly reward deficiency and stress-like anti-reward processes. And so, BPD may be reclassified as a \"traumatic personality stress disorder\" (TPSD) with ensuing common therapeutic strategies that may stabilize dopaminergic reward function such as psychedelic-assisted therapy. Integrated therapeutic strategies may be further supported by genetic studies aimed at assessing similarities between the two therapeutic entities. In this perspective we theorize that psychedelic assisted therapy (PAT) may play a role in the treatment of trauma induced personality disorders. This study identifies PAT as a pathway for treating both BPD and PTSD, proposing that reframing BPD as TPSD could lead to more effective, personalized interventions, ultimately improving the quality of life for those affected by trauma. Such a reclassification might also mitigate stigma, enhance our understanding of the underlying mechanisms, and optimize therapeutic interventions for a broader range of diagnostic categories characterized by anhedonia, negative affective states, hypervigilance, and dissociation.</p>","PeriodicalId":73582,"journal":{"name":"Journal of addiction psychiatry","volume":"8 2","pages":"161-165"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There a Natural, Non-addictive, and Non-anti-reward, Safe, Gene-based Solution to Treat Reward Deficiency Syndrome? KB220 Variants vs GLP-1 Analogs.","authors":"Edward Justin Modestino, Abdalla Bowirrat, David Baron, Panayotis K Thanos, Colin Hanna, Debasis Bagchi, Eric R Braverman, Catherine A Dennen, Rajendra D Badgaiyan, Aryeh R Pollack, Kai-Uwe Lewandrowski, Alireza Sharafshah, Mark S Gold, Kenneth Blum","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Reward deficiency syndrome (RDS) is an umbrella term encompassing a wide array of addictive behaviors that affect individuals across diverse spectra of society. Our research group has conducted a plethora of studies investigating the utilization of KB220 and its various iterations for addressing RDS, including: dopamine homeostasis, brain areas associated with dopamine, functional connectivity, qEEG, reductions of cravings, relapse prevention and detoxification, opioid-seeking and attenuation of intake, binge-drinking and withdrawal, driving under the influence (DUI), shopping and hoarding behaviors, memory decline, nightmares, paraphilias, attention deficit hyperactivity disorder (ADHD), eating disorders and weight loss, anger and stress reduction, and genetically customized compounds. In this review, we compare studies using KB220 (and variants) for these things with GLP-1 analogs. We suggest that KB220 (and its variants) demonstrate superiority over GLP-1 analogs for addressing all these issues, as evidenced by various reasons outlined herein, particularly their impact on the brain's reward cascade and dopamine homeostasis, all while avoiding antagonism of the reward system.</p>","PeriodicalId":73582,"journal":{"name":"Journal of addiction psychiatry","volume":"8 1","pages":"34-49"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy.","authors":"Foojan Zeine, Nicole Jafari, David Baron, Abdalla Bowirrat, Albert Pinhasov, Brian Norling, Kathleen Carter Martinez, Mohammad Nami, Nima Manavi, Keerthy Sunder, David M Rabin, Debasis Bagchi, Jag Khalsa, Mark S Gold, Daniel Sipple, Mojtaba Barzegar, Jothsna Bodhanapati, Waseem Khader, Paul Carney, Catherine A Dennen, Ashim Gupta, Igor Elman, Rajendra D Badgaiyan, Edward J Modestino, Panayotis K Thanos, Colin Hanna, Thomas McLaughlin, Jean Lud Cadet, Diwanshu Soni, Eric R Braverman, Debmalya Barh, John Giordano, Drew Edwards, J Wesson Ashford, Marjorie C Gondre-Lewis, Elizebeth Gilley, Kevin T Murphy, Kai-Uwe Lewandrowski, Alireza Sharafshah, Milan Makale, Brian Fuehrlein, Kenneth Blum","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>The opioid crisis in the last few decades has mounted to a global level, impacting all areas of socioeconomic, demographic, geographic, and cultural boundaries. Traditional treatments have not been deemed to show the degree of efficacy necessary to address the crisis. The authors of this review paper have set forth an unprecedented and in-depth look into multi-factorial determinants that have contributed to the opioid crisis becoming global and multi-faceted.</p><p><strong>Methods: </strong>For this narrative review/opinion article, we searched PsychINFO, PubMed, Google Scholar, and Web of Science databases to identify relevant articles on topics including the \"opioid crisis,\" \"opioid mechanisms,\" \"genetics and epigenetics,\" \"neuropharmacology,\" and \"clinical aspects of opioid treatment and prevention.\" Since this was not a systematic review the articles selected could represent unitential bias.</p><p><strong>Results: </strong>Despite some success achieved through Opioid Substitution Therapy (OST) in harm reduction, the annual mortality toll in the US alone surpasses 106,699 individuals, a figure expected to climb to 165,000 by 2025. Data from the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Survey on Drug Abuse and Health (NSDUH) reveals that approximately 21.4% of individuals in the US engaged in illicit drug use in 2020, with 40.3 million individuals aged 12 or older experiencing a Substance Use Disorder (SUD). Provisional figures from the Centers for Disease Control and Prevention (CDC) indicate a troubling 15% increase in overdose deaths in 2021, rising from 93,655 in 2020 to 107,622, with opioids accounting for roughly 80,816 of these deaths.</p><p><strong>Conclusions: </strong>We advocate reevaluating the \"standard of care\" and shifting towards inducing dopamine homeostasis by manipulating key neurotransmitter systems within the brain's reward cascade. We propose a paradigm shift towards a novel \"standard of care\" that begins with incorporating Genetic Addiction Risk Severity (GARS) testing to assess pre-addiction risk and vulnerability to opioid-induced addiction; emphasis should be placed on inducing dopamine homeostasis through safe and non-addictive alternatives like KB220, and comprehensive treatment approaches that address psychological, spiritual, and societal aspects of addiction through Awareness Integration Therapy (AIT).</p>","PeriodicalId":73582,"journal":{"name":"Journal of addiction psychiatry","volume":"8 1","pages":"50-95"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychostimulants for Children: Are We Over or Under Dosing?","authors":"Kenneth Blum, Catherine Dennen, Paul R Carney, Elizabeth Gilley, Panayotis K Thanos, Eric R Braverman, David Baron, Colin Hanna, Edward J Modestino, Mark S Gold, Igor Elman, Rajendra D Badgaiyan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An estimated 3% to 10% of school children meet the DSM-V criteria for ADHD (Attention-Deficit/Hyperactivity Disorder), however, to be over-diagnosed, the rate of children inappropriately diagnosed with ADHD (false positives) would have to be larger than the number of children with ADHD who are under-identified and not diagnosed (false negatives). Accordingly, a number of investigators take the position that under-treatment with psychostimulants, especially in children and adolescence, will result in continued ADHD symptomatology including future Substance Use Disorder (SUD). However, other researchers and clinicians believe otherwise and espouse laudable arguments for caution and prolonged methamphetamine treatment. While there is ongoing controversy of the role of genetics and epigenetics linked to ADHD, it seems clear that a number of dopaminergic genes and their risk polymorphisms act as DNA antecedents impacted by epigenetic induced methylation. Our hypothesis and literature review suggest that one possible solution is to embrace non addictive interventions to induce global dopamine homeostasis.</p>","PeriodicalId":73582,"journal":{"name":"Journal of addiction psychiatry","volume":"7 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10349388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are We Getting High Cause the Thrill is Gone?","authors":"Kenneth Blum, Thomas Mclaughlin, Mark S Gold, Marjorie C Gondre-Lewis, Panayotis K Thanos, Igor Elman, David Baron, Abdalla Bowirrat, Debamyla Barh, Jag Khalsa, Colin Hanna, Nicole Jafari, Foojan Zeine, Eric R Braverman, Catherine Dennen, Milan T Makale, Miles Makale, Keerthy Sunder, Kevin T Murphy, Rajendra D Badgaiyan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the USA alone, opioid use disorder (OUD) affects approximately 27 million people. While the number of prescriptions may be declining due to increased CDC guidance and prescriber education, fatalities due to fentanyl-laced street heroin are still rising. Our laboratory has extended the overall concept of both substance and non-substance addictive behaviors, calling it \"Reward Deficiency Syndrome (RDS).\" Who are its victims, and how do we get this unwanted disorder? Is RDS caused by genes (Nature), environment (Neuro-epigenetics, Nurture), or both? Recent research identifies resting-state functional connectivity in the brain reward circuitry as a crucial factor. Analogously, it is of importance to acknowledge that the cumulative discharge of dopamine, governed by the nucleus accumbens (NAc) and modulated by an array of additional neurotransmitters, constitutes a cornerstone of an individual's overall well-being. Neuroimaging reveals that high-risk individuals exhibit a blunted response to stimuli, potentially due to DNA polymorphisms or epigenetic alterations. This discovery has given rise to the idea of a diminished 'thrill,' though we must consider whether this 'thrill' may have been absent from birth due to high-risk genetic predispositions for addiction. This article reviews this issue and suggests the general concept of the importance of \"induction of dopamine homeostasis.\" We suggest coupling a validated genetic assessment (e.g., GARS) with pro-dopamine regulation (KB220) as one possible frontline modality in place of prescribing potent addictive opioids for OUD except for short time harm reduction. Could gene editing offer a 'cure' for this undesirable genetic modification at birth, influenced by the environment and carried over generations, leading to impaired dopamine and other neurotransmitter imbalances, as seen in RDS? Through dedicated global scientific exploration, we hope for a future where individuals are liberated from pain and disease, achieving an optimal state of well-being akin to the proverbial 'Garden of Eden'.</p>","PeriodicalId":73582,"journal":{"name":"Journal of addiction psychiatry","volume":"7 1","pages":"5-516"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139076131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}